

Rodent Oat1 vs. Human OAT1

Introduction: Rodent organic anion transporter 1 (Oat1) of the Slc22 gene family are polyspecific transporters mainly located in kidneys. Several Oats are expressed also in liver and brain. Mouse (m) Oat1 and rat (r) Oat1 consist of 551 and 545 amino acids, respectively. They posses an amino acids sequence identity of 86% and 87% compared to the homologouse gene of human OAT1. OATs interact with endogenous metabolic end products such as urate and acidic neurotransmitter metabolites, as well as with a multitude of widely used drugs, including antibiotics, antihypertensiva, antivirals, anti-inflammatory drugs, diuretics and uricosurics. Thereby, OATs play an important role in renal and hepatic drug elimination and have an impact on pharmacokinetics. Since OATs are typically found at boundary epithelia, these transporters play an important role in absorption, distribution and excretion of drugs. Moreover, OATs can be the site of drug-drug interactions during competition of two or more drugs for the same transporter and mediate cell damage by transporting cytotoxic compounds. For human OAT1 regulatory agencies (FDA, EMA and Japan) decided that renal eliminated drugs has to be tested for drug-drug interaction, in vitro. Concerning that ADME-Tox related data are initially generated in rodents, it is important to consider species differences *in vivo* as well as *in vitro*. Therefore, PortaCeIITec Biosciences GmbH provides comparable cell systems, to detect substrate and inhibitory differences between human and rodent drug transporters, *in vitro*.

Methods: PortaCellTec (PCT) generated HEK293 cell lines stably expressing mouse (m)Oat1, rat (r)Oat1 and human (h) OAT1 transporter proteins and validated each cell-transporter system with a reference substrate (³H-PAH (p-aminohippuric acid)) and different inhibitors. To perform uptake experiments, three days after cell seeding, the uptake was initiated by adding the reference substrate in the absence and presence of an inhibitor. To terminate the uptake cells were washed three times with cold assay buffer. The radio-labelled content (³H) of each cell lysate was analyzed by liquid scintillation counting.



www.portacelltec.de



Rodent Oat3 vs. Human OAT3

Introduction: Rodent organic anion transporter 3 (Oat3) of the Slc22 gene family are polyspecific transporters mainly located in kidneys. Several Oats are expressed also in liver and brain. Mouse (m) Oat3 and rat (r) Oat3 consist of 536 and 537 amino acids, respectively. They posses an amino acids sequence identity of 79% and 78% compared to the homologous gene of human hOAT3. OATs interact with endogenous metabolic end products such as urate and acidic neurotransmitter metabolites, as well as with a multitude of widely used drugs, including antibiotics, antihypertensiva, antivirals, anti-inflammatory drugs, diuretics and uricosurics. Thereby, OATs play an important role in renal and hepatic drug elimination and have an impact on pharmacokinetics. Since OATs are typically found at boundary epithelia, these transporters play an important role in absorption, distribution and excretion of drugs. Moreover, OATs can be the site of drugdrug interactions during competition of two or more drugs for the same transporter and mediate cell damage by transporting cytotoxic compounds. For human hOAT3 regulatory agencies (FDA, EMA and Japan) decided that renal eliminated drugs has to be tested for drug-drug interaction, in vitro. Concerning that ADME-Tox related data are initially generated in rodents, it is important to consider species differences in vivo as well as in vitro. Therefore, PortaCellTec Biosciences GmbH provides comparable cell systems, to detect substrate and inhibitory differences between human and rodent drug transporters, in vitro.

Methods: PortaCellTec (PCT) generated HEK293 cell lines stably expressing mouse (m)Oat3, rat (r)Oat3 and human (h)OAT3 transporter proteins and validated each cell-transporter system with a reference substrate (3H-estrone-sulfate (ES)) and different inhibitors. To perform uptake experiments, three days after cell seeding, the uptake was initiated by adding the reference substrate in the absence and presence of an inhibitor. To terminate the uptake cells were washed three times with cold assay buffer. The radio-labelled content (³H) of each cell lysate was analyzed by liquid scintillation counting.

mOat3 – Slc22a8				rOat3 – Slc22a8				
Substrate	Inhibitor	Kinetic parameters	References	Substrate	Inhibitor	Kinetic parameters	References	
Estrone- sulfate		K _m = 70±19 μM	K _m = 12.2 μM (VanWert, 2008)	Estrone- sulfate		$K_m = 38 \pm 11 \mu M$	$K_m = 7.1 \mu$ M (Minematsu, 2008) $K_m = 34 \mu$ M (Hasegawa, 2003)	
Estrone- sulfate	Probenecid	$IC_{50} = 6.5 \pm 1.6 \ \mu M$	$K_i = 4.6 \mu M$ (Eraly, 2008)	Estrone- sulfate	Probenecid	$IC_{50} = 13 \pm 4 \ \mu M$	IC50 =6.0 µM (Khamdang, 2004)	
Figure 3Concentration dependentFigure 4Inhibition of mOat3 mediatedmOat3 mediated ES net-uptakeES net uptake by Probenecid					Figure 7 Concentration dependentFigure 8 Inhibition of rOat3 mediated ESrOat3 mediated ES net-uptakenet uptake by Probenecid			
2000 1500 ()uuujuujuu ()uuujuujuujuu ()uuujuujuujuu ()uuujuujuujuu ()uuujuujuu ()uuujuujuu ()uuujuujuu ()uuujuujuu ()uuujuujuu ()uuujuujuu ()uuujuujuujuu ()uuujuujuujuu ()uuujuujuujuu ()uuujuujuujuujuu ()uuujuujuujuujuu ()uuujuujuujuujuu ()uuujuujuujuujuujuu ()uuujuujuujuujuujuujuujuu ()uuujuujuujuujuujuujuujuujuujuujuujuujuu	Km = 7 Vmax	12 10 10 10 10 10 10 10 10 10 10	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	600 - avtraction - avtractio	Km = 34 Vmax = 100 200 300 ES (µM)	(%) averation (%	140 100 100 100 100 100 100 100	
hOAT3 – SLC22A8					hOAT3 vs. moat3			
Substrate	Inhibitor	Kinetic	References	Olmesartan -	10 µM Drugs		100 µM Drugs	
Estrone- sulfate Estrone- sulfate	 Probenecid	$K_{m} = 20\pm5 \ \mu M$ IC ₅₀ = 23±2 μ M	K _m = 6.3 μM (Ueo, 2005) C ₅₀ = 4.7 μM (Srimaroeng 2005)	Glibenclamid - Furosemid - Benzbromarone - Losartan - Indomethacin - Valsartan - MK571 - Sulfasalazine - Burnetanid - Fluvastatin -	hOAT3 moat3		Andrewski - Locatan - Incention - Inc	
Figure 5 Concentration dependent Figure 6 Inhibition of hOAT3 mediated hOAT3 mediated ES net-uptake ES net uptake by Probenecid							Probencial Constraints of the second	
120 100 (buol/ugbroterin/win) 0 0 0 0 0 0 0 2	• Km - Vma 0 40 60 80 ES (µM)	*20 ± 5 µM x = 105 ± 9 pmol/mg/min 100 120 140 120 140	$C_{50} = 23 \pm 2 \mu M$ $C_{50} = 23 \pm 2 \mu M$ $C_{50} = 23 \pm 2 \mu M$ D_{10} $D_$	Tetracyclin - Rifampion Cefadroxii - 	20 0 20 40 Inhibitory effect on hOA' mediated ³ H-ES net i 10 μM Pe	C 0 60 80 100 T3 and meal3 uptake (%) sticides C Epc Dim In Dim	Digono Celadorol Additional relargadin dosportinal dosportinal deserver me server Ministry of Relargadin deserver me distance deserver me deserver me distance deserver me deserver me deserv	
References: Paragati: Vanwert AL, et al. Organic Anion Transporter 3 (oat3/sic22a8) Interacts With Carboxyfluoroquinolones, Mol Pharmacol 2008; 74: 122–131 Lindan Eraly SA, et al. Organic Anion Transporter 3 Inhibitors as Potential Novel Antihypertensives. Pharmacol Res 2008; 58: 257–261. Primicab Minematsu T, et al. Role of Organic Anion Transporters in the Pharmacokinetics of Zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4 Primicab Propionate Receptor Antagonist, in Rats. Drug Metab Dispos 2008; 36: 1496–1504. Bernethrin Pharmacol Exp Ther 2003; 305: 1087–1097. Glybhoat Khamdang S, et al. Interactions of Human - And Rat-Organic Anion transporters With Pravastatin and Cimetidine. J Pharmacol Sci 2004; 94: 197–202. Opermethrin Ueo H, Motohashi H, Katsura T, Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison Srimaroeng C et al. Interactions of stevioside and steviol with renal organic anion transporters in S2 cells and mouse Pharm Res 2005; 22: 858–866.						- Cr - Dr 	tamethrin - -40 -20 0 20 40 60 80 100 Inhibitory effect on hOAT3 and moat3 mediated ¹ / ₂ LFS Pot unitate ^(b)	